Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec 11;3(4):1004–1018. doi: 10.3390/vaccines3041004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

WT1-CTLs induced by WT1_126–134 (HLA-A*02:01), WT1_235–243 (HLA-A*24:02), or WT1_332-347 peptide-pulsed DC vaccination: (a) modified WT1-peptide/HLA-A*24:02 tetramer analysis from case 1. Percentages represent the proportion of tetramer-positive cells in the total CD8⁺ T-cell population; (b) interferon (IFN)-γ-producing clones on ELISPOT assays with WT1_235–243 peptide (HLA-A*24:02) from case 1; (c) comparison of WT1-peptide/HLA-A*24:02 tetramer analyses before and after DC vaccination from case 2; (d) IFN-γ-producing clones on ELISPOT assay with WT1_235–243 peptide (HLA-A*24:02; upper panel) and WT1_126–134 peptide (HLA-A*02:01; lower panel) from case 2; (e) modified WT1-peptide/HLA-A*24:02 tetramer analysis from case 3; and (f) IFN-γ-producing clones on ELISPOT assay with WT1_235–243 peptide (HLA-A*24:02; upper panel) and WT1_332–347-class II peptide (HLA-DPB1*05:01; lower panel) from case 3. WT1, Wilms’ tumor 1; CTL, cytotoxic T cell; HLA, human leukocyte antigen; DC, dendritic cell; IFN, interferon; ELISPOT, enzyme-linked immunosorbent spot; * p < 0.05 indicates statistical significance using Dunnett’s test; Black bars, WT1 and white bars, negative control.

WT1-CTLs induced by WT1_126–134 (HLA-A*02:01), WT1_235–243 (HLA-A*24:02), or WT1_332-347 peptide-pulsed DC vaccination: (a) modified WT1-peptide/HLA-A*24:02 tetramer analysis from case 1. Percentages represent the proportion of tetramer-positive cells in the total CD8⁺ T-cell population; (b) interferon (IFN)-γ-producing clones on ELISPOT assays with WT1_235–243 peptide (HLA-A*24:02) from case 1; (c) comparison of WT1-peptide/HLA-A*24:02 tetramer analyses before and after DC vaccination from case 2; (d) IFN-γ-producing clones on ELISPOT assay with WT1_235–243 peptide (HLA-A*24:02; upper panel) and WT1_126–134 peptide (HLA-A*02:01; lower panel) from case 2; (e) modified WT1-peptide/HLA-A*24:02 tetramer analysis from case 3; and (f) IFN-γ-producing clones on ELISPOT assay with WT1_235–243 peptide (HLA-A*24:02; upper panel) and WT1_332–347-class II peptide (HLA-DPB1*05:01; lower panel) from case 3. WT1, Wilms’ tumor 1; CTL, cytotoxic T cell; HLA, human leukocyte antigen; DC, dendritic cell; IFN, interferon; ELISPOT, enzyme-linked immunosorbent spot; * p < 0.05 indicates statistical significance using Dunnett’s test; Black bars, WT1 and white bars, negative control.